Diagnosis and management of acute myeloid leukemia with mutated CEBPA using CEBPA-Trass, a targeted sequencing approach
Year: 2026
Type: article
Abstract: Acute myeloid leukemia (AML) with mutated CEBPA (CEBPA-AML) was first recognized as a distinct subtype associated with favorable prognosis in 2002, and its diagnostic criteria and clinical management have been refined over time. However, several challenges remain, including the lack of accurate mutation-based methods for measurable residual disease (MRD) detection. Here, we developed a targeted next-generation sequencing approach for the CEBPA gene, which uses adapter-free PCR amplification of hotspot regions followed by paired-end sequencing to improve analytical performance (termed CEBPA-Trass), and evaluated its clinical performance in samples from the WT1-AM-04 study. CEBPA-Trass successfully detected a cryptic long insertion missed by conventional short-read sequencing. Analytical validation showed higher background for missense variants, whereas insertions or deletions involving three or more base pairs were rarely detected in negative controls and typically below 10⁻⁴, indicating high analytical specificity. Dilution experiments further showed linear detection of insertions or deletions involving three or more base pairs with a limit of detection of 10⁻⁴ -10⁻⁵, comparable to the sensitivity of real-time PCR-based MRD assays, and aligned with the in-frame mutation patterns currently associated with favorable-risk CEBPA-AML. Clinically, CEBPA-Trass-based MRD assessment significantly stratified relapse risk after both first and last consolidation therapy. Specifically, the assessment after last consolidation showed that more than 80% of MRD-positive patients relapsed, whereas more than 80% of MRD-negative patients remained in remission for over two years. These findings suggest that CEBPA-Trass enables accurate mutation-based MRD monitoring and may improve both the diagnosis and risk stratification of patients with CEBPA-AML.
Source: Blood Advances
Authors: Jun Nakata, Daisuke Motooka, Hiroyuki Yamano, Yuki Takada, Hiroko Nakajima, Fumihiro Fujiki, Soyoko Morimoto, Yoshiki Nakae, Manabu Kawakami, Yuta Katayama, Ryota Imanaka, Junya Kuroda, Taku Tsukamoto, Takayuki Ikezoe, Masahiko Fukatsu, Atsushi Satake, Hideaki Yoshimura, Takashi Sonoki, Hiroki Hosoi, Norimitsu Kadowaki, Osamu Imataki, Shigeki Ito, Tatsuo Oyake, Kazunori Murai, Shuichi Ota, Masayoshi Masuko, Yasuhiko Shibasaki, Tatsuya Imi, Makoto Onizuka, Takeshi Maeda, Hitoshi Hanamoto, Kensuke Usuki, Noboru Asada, Yusuke Oji, Akihiro Tsuboi, Yoshihiro Oka, Atsushi Kumanogoh, Haruo Sugiyama
Institutions: The University of Osaka, Research Institute for Microbial Diseases, The University of Osaka, Nippon Life Hospital, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Kyoto Prefectural University of Medicine, Fukushima Medical University, Kansai Medical University, Wakayama Medical University, Kagawa University, Iwate Medical University, Iwate Prefectural Central Hospital, Sapporo Hokuyu Hospital, Niigata University, Kanazawa University, Tokai University, Kurashiki Central Hospital, Kindai University Nara Hospital, Kindai University, Teikyo University Hospital, Mizonokuchi, Teikyo University, Okayama University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,800
OpenAlex ID: W7236823051
